



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number

10/669,869

Filing Date

September 23, 2003

First Named Inventor

Cyrus Rustam Kumana

Group Art Unit

1616

Examiner Name

Frank I. Choi

Attorney Docket Number

UHK 00091

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ¹
		ABROUN, et al., "Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor alpha [corrected]", <i>Blood</i> , 103(6):2291-8 (2004).	
		AKAY and GAZITT, "Arsenic trioxide selectively induces early and extensive apoptosis via the APO2/caspase-8 pathway engaging the mitochondrial pathway in myeloma cells with mutant p53", <i>Cell Cycle</i> , 2(4):358-68 (2003).	
		ALT, et al., "Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation" <i>Genes Dev</i> , 14:3102-14 (2000).	
		AU, et al., "Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide", <i>Br J Haematol</i> , 117(1):130-2 (2002).	
		BAHLIS, et al., "Feasibility and correlates of arsenic trioxide combined with ascorbic acid-mediated depletion of intracellular glutathione for the treatment of relapsed/refractory multiple myeloma", <i>Clin Cancer Res</i> , 8(12):3658-68 (2002).	
		BERENSON, et al., "A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma", <i>Clin Lymphoma</i> , 5(2):130-4 (2004).	
		BURKE, et al., "BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice", <i>J Biol Chem</i> , 278:1450-6 (2003).	
		CAMACHO, et al., "Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide", <i>J. Clin. Oncol.</i> , 18:2620-5 (2000).	
		CARPENTER, "Employment of the epidermal growth factor receptor in growth factor-independent signaling pathways", <i>J Cell Biol</i> , 146(4):697-702 (1999).	
		CATLEY, et al., "Perspectives for combination therapy to overcome drug-resistant multiple myeloma", <i>Drug Resist Updat</i> , 8(4):205-18 (2005).	

Examiner's
Signature

Date Considered

*EXAMINER: Initial If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/669,869
		Filing Date	September 23, 2003
		First Named Inventor	Cyrus Rustam Kumana
		Group Art Unit	1616
		Examiner Name	Frank I. Choi
Sheet	2	of	8
		Attorney Docket Number	UHK 00091

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		CHEN, et al., "Use of arsenic trioxide (As ₂ O ₃) in the treatment of acute promyelocytic leukemia (APL): I. As ₂ O ₃ exerts dose-dependent dual effects on APL cells" <i>Blood</i> , 89(9):3345-53 (1997).	
		CHOONG and COHEN, "Epidermal growth factor receptor directed therapy in head and neck cancer", <i>Crit Rev Oncol Hematol.</i> , 57(1):25-43 (2006).	
		COHEN, et al., "The expanding role of systemic therapy in head and neck cancer", <i>J Clin Oncol.</i> , 22(9):1743-52 (2004).	
		COLE, et al., "Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event", <i>Biochem J.</i> , 377:249-55 (2004).	
		CROSS, et al., "Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B", <i>Nature</i> , 378:785-9 (1995).	
		DAVISON, et al., "JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells", <i>Blood</i> , 103(9):3496-502 (2004).	
		DEL RAZO, et al., "Stress proteins induced by arsenic", <i>Toxicol Appl Pharmacol.</i> , 177(2):132-48 (2001).	
		DIEHL, et al., "Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization", <i>Genes Dev.</i> , 12:3499-511 (1998).	
		DIEHL, et al., "Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway", <i>Genes Dev.</i> , 11:957-72 (1997).	
		FAN, et al., "Phospholipase C-independent activation of glycogen synthase kinase-3beta and C-terminal Src kinase by Galphag", <i>J Biol Chem.</i> , 278:52432-6 (2003).	
		FERLIN, et al., "Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway", <i>Br J Haematol.</i> , 111(2):626-34 (2000).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/669,869
		Filing Date	September 23, 2003
		First Named Inventor	Cyrus Rustam Kumana
		Group Art Unit	1616
		Examiner Name	Frank I. Choi
Sheet	3	of	8
		Attorney Docket Number	UHK 00091

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		FORSTPOINTER, et al. "The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group" <i>Blood</i> , 104:3064-71 (2004).	
		GARTENHAUS, et al., "Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state", <i>Clin Cancer Res.</i> , 8(2):566-72 (2002).	
		GOY, et al., "Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma" <i>J Clin Oncol</i> , 23:667-75 (2005).	
		GRANDIS, et al., "Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival". <i>J Natl Cancer Inst.</i> 90:824-32 (1998)	
		GUO, et al., "Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis" <i>Oncogene</i> , 24:2599-612 (2005).	
		GUO, et al., "Post-transcriptional regulation of cyclin D1 expression during G2 phase" <i>Oncogene</i> , 21:7545-56 (2002).	
		HARTIGAN, et al., "Glycogen synthase kinase 3beta is tyrosine phosphorylated by PYK2", <i>Biochem Biophys Res Commun.</i> , 284:485-9 (2001).	
		HARTIGAN, et al., "Transient increases in intracellular calcium result in prolonged site-selective increases in Tau phosphorylation through a glycogen synthase kinase 3beta-dependent pathway", <i>J Biol Chem</i> , 274:21395-401 (1999).	
		HICKE, "Protein regulation by monoubiquitin", <i>Nat Rev Mol Cell Biol</i> , 2:195-201 (2001).	
		HUANG, et al., "Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukaemia", <i>Br J Haematol.</i> , 103(4):1092-5 (1998).	
		HUBBARD and TILL, "Protein tyrosine kinase structure and function", <i>Annu Rev Biochem.</i> , 69:373-98 (2000).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/APTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/669,869
		Filing Date	September 23, 2003
		First Named Inventor	Cyrus Rustam Kumana
		Group Art Unit	1616
		Examiner Name	Frank I. Choi
Sheet	4	of	8
		Attorney Docket Number	UHK 00091

OTHER ART — NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		HUGHES, et al., "Modulation of the glycogen synthase kinase-3 family by tyrosine phosphorylation", <i>EMBO J</i> , 12:803-8 (1993).	
		HUSSEIN, et al., "Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma", <i>Br J Haematol.</i> , 125(4):470-6 (2004).	
		JANNE, "Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations", <i>Semin Oncol.</i> , 32(6 Suppl 10):S9-15 (2005).	
		JEMAL, et al., "Cancer statistics, 2005", <i>CA Cancer J Clin.</i> , 55(1):10-30 (2005).	
		KAUFFMANN-ZEH, et al., "Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB", <i>Nature</i> , 385:544-8 (1997).	
		KAUFMANN, et al., "Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma", <i>Blood</i> , 104:2269-71 (2004).	
		KIM, et al., "The novel tyrosine kinase ZAK1 activates GSK3 to direct cell fate specification", <i>Cell</i> , 99:399-408 (1999).	
		KWAK, et al., "IkappaB kinase alpha regulates subcellular distribution and turnover of cyclin D1 by phosphorylation", <i>J Biol Chem</i> , 280:33945-52 (2005).	
		KWONG, et al., "Delicious poison: arsenic trioxide for the treatment of leukemia", <i>Blood</i> , 89(9):3487-8 (1997).	
		KWONG, et al., "Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study", <i>Am J Hematol.</i> , 66:274-9 (2001).	
		KWONG, "Arsenic trioxide in the treatment of haematological malignancies", <i>Expert Opin Drug Saf.</i> , 3(6):589-97 (2004).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/669,869
				Filing Date	September 23, 2003
				First Named Inventor	Cyrus Rustam Kumana
				Group Art Unit	1616
				Examiner Name	Frank I. Choi
				Attorney Docket Number	UHK 00091
Sheet	5	of	8		

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Y ²
		LALEMAND-BREITENBACH, et al., "Role of promyelocytic leukemia (PML) smulation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation", <i>J Exp Med</i> , 193(12):1361-71 (2001).	
		LENZ, et al., "Immunotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)", <i>J Clin Oncol</i> , 23:1984-92 (2005).	
		LESORT, et al., "Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase", <i>J Neurochem</i> , 72:576-84 (1999).	
		LING, et al., "NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176", <i>Proc Natl Acad Sci U S A</i> , 95:3792-7 (1998).	
		LIU, et al., "Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL", <i>Blood</i> , 101(10):4078-87 (2003).	
		LU, et al., "Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report", <i>Blood</i> , 99(9):3136-43 (2002).	
		MALININ, et al., "MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1", <i>Nature</i> , 385:540-4 (1997).	
		MARMOR and YARDEN, "Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases", <i>Oncogene</i> , 23(11):2057-70 (2004).	
		MOSESSON, et al., "Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation", <i>J Biol Chem</i> , 278(24):21323-6 (2003).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/669,869
				Filing Date	September 23, 2003
				First Named Inventor	Cyrus Rustam Kumana
				Group Art Unit	1616
				Examiner Name	Frank I. Choi
Sheet	6	of	8	Attorney Docket Number	UHK 00091

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		MUNSHI, "Arsenic trioxide: an emerging therapy for multiple myeloma", <i>Oncologist</i> , 6 Suppl 2:17-21 (2001).	
		NI, et al., "Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia", <i>Chin Med J (Engl)</i> , 111(12):1107-10 (1998).	
		NIU, et al., "Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients", <i>Blood</i> , 94(10):3315-24 (1999).	
		O'CONNOR, et al., "Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma", <i>J Clin Oncol</i> , 23:676-84 (2005).	
		OHNISHI, et al., "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia", <i>Ann Intern Med</i> , 133(11):881-5 (2000).	
		PARK, et al., "Arsenic trioxide-mediated growth inhibition in M2/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis", <i>Cancer Res</i> , 60(11):3065-71 (2000).	
		POMERANTZ and GRANDIS, "The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy", <i>Semin Oncol</i> , 31(6):734-43 (2004).	
		QIAN, et al., "New perspectives in arsenic-induced cell signal transduction", <i>J Inorg Biochem</i> , 96(2-3):271-8 (2003).	
		QIANG, et al., "Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk", <i>Blood</i> , 99(11):4138-46 (2002).	
		ROMAQUERA, et al., "High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine" <i>J Clin Oncol</i> , 23:7013-23 (2005).	
		ROODMAN, "Pathogenesis of myeloma bone disease", <i>Blood Cells Mol Dis</i> , 32(2):290-2 (2004).	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/669,869
		Filing Date	September 23, 2003
		First Named Inventor	Cyrus Rustam Kumana
		Group Art Unit	1616
		Examiner Name	Frank I. Choi
		Attorney Docket Number	UHK 00091
Sheet	7	of	8

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	†
		SAYAS, et al., "GSK-3 is activated by the tyrosine kinase Pyk2 during LPA1-mediated neurite retraction", <i>Mol Biol Cell</i> , 17:1834-44 (2006).	
		SHEN, et al., "Use of arsenic trioxide (As ₂ O ₃) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients", <i>Blood</i> , 89(9):3354-60 (1997).	
		SHERR, "Cancer cell cycles" <i>Science</i> , 274:1672-7 (1996).	
		SHERR, et al., "The RB and p53 pathways in cancer" <i>Cancer Cell</i> , 2:103-112 (2002).	
		SIMEONOVA, et al., "c-Src-dependent activation of the epidermal growth factor receptor and mitogen-activated protein kinase pathway by arsenic. Role in carcinogenesis", <i>J Biol Chem</i> , 277(4):2945-50 (2002).	
		SOIGNET, et al., "Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide", <i>N Engl J Med</i> , 339(19):1341-8 (1998).	
		SOIGNET, et al., "United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia", <i>J Clin Oncol</i> , 19(18):3852-60 (2001).	
		STERNSDORF, et al., PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia", <i>Mol Cell Biol</i> , 19(7):5170-8 (1999).	
		SWERDLOW, et al., Mantle Cell Lymphoma, in Jaffe, E.S. et al. (ed.), WHO Classification of Tumors, (2001) 168-170.	
		TAI, et al., "Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling", <i>Cancer Res</i> , 63(18):5850-8 (2003).	
		TALLMAN, et al., "Acute promyelocytic leukemia: evolving therapeutic strategies", <i>Blood</i> , 99(3):759-67 (2002).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. ‡ See attached Kinds of U.S. Patent Documents. § Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ** Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *** Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/APTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/669,869
		Filing Date	September 23, 2003
		First Named Inventor	Cyrus Rustam Kumana
		Group Art Unit	1616
		Examiner Name	Frank I. Choi
Sheet	8	of	8
		Attorney Docket Number	UHK 00091

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Y ²
		The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's Lymphoma", <i>Blood</i> , 89:3909-3918 (1997).	
		TSUJIMOTO, et al., "Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11;14) chromosome translocation", <i>Nature</i> , 315:340-3 (1985).	
		TSUJIMOTO, et al., "Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation" <i>Science</i> , 224:1403-6 (1994).	
		VAN DE DONK, et al., "Growth factors and antiapoptotic signaling pathways in multiple myeloma", <i>Leukemia</i> , 19(12):2177-85 (2005).	
		VANHAESBROECK, et al., "Phosphoinositide 3-kinases: a conserved family of signal transducers", <i>Trends Biochem Sci</i> , 22:267-72 (1997).	
		WITZIG "Current treatment approaches for mantle-cell lymphoma", <i>J Clin Oncol</i> , 23:6409-14 (2005).	
		WITZIG, et al., "Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma", <i>J Clin Oncol</i> , 23:5347-56 (2005).	
		YAMAUCHI, et al., "Metabolism and excretion of orally administered arsenic trioxide in the hamster", <i>Toxicology</i> , 34(2):113-21 (1985).	
		YANG and FRENKEL, "Arsenic-mediated cellular signal transduction, transcription factor activation, and aberrant gene expression: implications in carcinogenesis", <i>Environ Pathol Toxicol Oncol</i> , 21(4):331-42 (2002).	

Examiner's Signature	/Frank Choi/	Date Considered	03/11/2008
----------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.